Crowdonomics
All companies
Bot Image logo

Bot Image

Operating

Bot Image, Inc.

Healthcare · Omaha, NE

BotImage is a medical artificial intelligence company that specializes in MRI. Our premiere product is ProstatID™, a software that supports accurate diagnosis of prostate cancer.

Post-money valuation ⓘ
$11.0M
As of Nov 2019 · from Reg CF Offering (2019) · pre-money + amount raised, not a traded price
Total raised
$4,398,628
Crowd $60K · Private $4.3M · 6 rounds since 2019
Latest share price
$15.75
Reg CF · Class B Common Stock · Jun 2019 offering price

Financials

FY2017–FY2021 · from SEC filings · hover any figure for its source
$3.7M
−$467K
2017
$5.3M
$299K
2018
$0
2019
$0
2020
$0
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2017 reviewed
FY2018 reviewed
FY2019
FY2020 unaudited
FY2021 unaudited
Income statement
Revenue
$3,656,175
$5,314,728
$0
$0
$0
Cost of goods sold
$217,686
$299,466
$0
$0
$0
Gross margin
94%
94%
—
—
—
Net income
-$467,118
$298,985
$0
$0
$0
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$137,814
$0
$414
$414
$269
Accounts receivable
$521,709
$934,348
$0
$0
$0
Total assets
$3,190,949
$3,921,159
$198,377
$613,228
$650,370
Short-term debt
$1,209,092
$2,151,021
$23,926
$24,655
$10,000
Long-term debt
$712,223
$663,404
$303,408
$110,945
$169,948
Total liabilities
$1,921,315
$2,814,425
$327,334
$135,600
$179,948
Other
Headcount
—
5
5
5
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$10.9M
pre-money
Reg CF · Class B Common · Jun 2019

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Principal holders% as the filing states it, Apr 29, 2022

  • ScanMed LLC665,348 Class A Common Stock100.0%of Class A

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $200KInvestors 1
Raised $280KInvestors 1
Raised $1MInvestors 1
Raised $1.4MInvestors 1
Raised $60.1K / $1.1MInvestors 67Post-money $11M
Raised $1.4MInvestors 5

Team

6 people
Dr. Randall Jones, PhDFounder
Founder & CEO

Dr. Jones is a successful entrepreneur with over 20 years experience of upper level management in the MRI industry. As an accomplished inventor holding over a dozen patents, he has effectively grown ScanMed 80% per year for the last three consecutive years by recognizing and meeting both clinical and business needs with innovative product solutions. With the combination of a background as a highly-trained USAF technician, PhD of EE and MRI physics, and MBA, Dr. Jones has lead ScanMed to become a world leader in MRI RF systems and MRI coil development and diagnostics by setting the record for time to market on new devices, contract engineering, and manufacturing.

Melanie JonesFounder
EVP Sales & Marketing

Melanie is a highly accomplished sales and marketing executive with over 20 years of leadership experience across multiple industries. Melanie helps develop strategies to bring ScanMed’s innovative products to market, meet clients needs, and break into new international markets. She also works closely with the sales and marketing, manufacturing, repair, and customer service teams to ensure the highest level of customer satisfaction for both new products and repairs.

Randall Jones
CEO, Principal Executive Officer and Director, Principal Financial Officer and Principal Accounting Officer
Natalie Hussey
Director of Marketing

An expert in brand management, business intelligence, and strategic market development, Natalie works closely with the product development team to educate customers about the pioneering products at BotImage. In addition, she manages public relations, oversees advertising strategy, and supports the sales staff to help break into new markets.

Dr. John Feller, MD
Clinical Advisor

Dr. John F. Feller is a founding partner of Desert Medical Imaging, currently the owner and Medical Director of the practice. He is board-certified as a Diagnostic Radiologist with sub-specialties in Orthopedic & Sports Medicine Imaging, Body MRI, and holds a Level II Cardiac CT certification. Dr. Feller is also a partner in China’s first American-owned multi-disciplinary outpatient healthcare facility, and serves as director of radiology.

Ethn Ulrich
Project Manager

Ethan is an engineer with 8 years experience in biomedical engineering and 6 years experience in medical imaging. He received his undergraduate degree in engineering from Dordt College in 2012. His doctoral work in Biomedical Engineering at the University of Iowa involved machine learning, biostatistics, medical image analysis, and medical software design. He currently utilizes his skills as lead software developer to design, test, and release advanced diagnostic software with the goal of assisting physicians and improving the quality of life for patients

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 3 of 7 annual reports (FY2019–FY2025)

67 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

  • Form DOct 20, 20250001778258-25-000005
    EDGAR
  • Form DOct 20, 20250001778258-25-000004
    EDGAR
  • Form DOct 16, 20250001778258-25-000003
    EDGAR
  • Form C-TRMar 14, 20230001778258-23-000001
    EDGAR
  • Form C-UOct 7, 20220001665160-22-002719
    EDGAR
  • Form C-ARApr 29, 20220001665160-22-001191
    EDGAR
  • Form DJun 7, 20210001778258-21-000002
    EDGAR
  • Form C-ARApr 29, 20210001665160-21-000722
    EDGAR
Source: SEC EDGARCIK 0001778258NEShare price $15.75Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.